Expression Pathology, Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
May 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for CMET protein SRM/MRM assay (US 10,302,656) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 2 fees due Mar 8 to 22, 2027 · next Mar 8
- 1 fee due Jul 21, 2027The maintenance fee for Methods for treating Her2-positive breast cancer (US 10,537,576) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 2 fees due Aug 9 to 16, 2027 · next Aug 9
- 2 fees due Sep 3 to 10, 2027 · next Sep 3
- 3 fees due Oct 12 to 14, 2027 · next Oct 12
Recent changes
- 6 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,609,345 | Diagnosis of Diseases and Conditions by Analysis of Histopathologically Processed Biological Samples Using Liquid Tissue Preparations In force · High confidence | In force | High confidence | |
| US 9,417,246 | Insulin Receptor Substrate 1 (IRS1) Protein SRM/MRM Assay In force · High confidence | In force | High confidence | |
| US 9,139,864 | c-Src selected reaction monitoring assay In force · From the USPTO record | In force | From the USPTO record | |
| US 10,302,656 | CMET protein SRM/MRM assay In force · From the USPTO record | In force | From the USPTO record | |
| US 9,128,102 | Her3 protein SRM/MRM assay In force · From the USPTO record | In force | From the USPTO record | |
| US 10,215,761 | BCL-2-LIKE Protein 11 Srm/Mrm Assay In force · Low confidence | In force | Low confidence | |
| US 9,551,719 | BCL-2-like protein 11 SRM/MRM assay In force · From the USPTO record | In force | From the USPTO record | |
| US 10,577,641 | Truncated Her2 SRM/MRM assay In force · From the USPTO record | In force | From the USPTO record | |
| US 9,372,195 | cMET protein SRM/MRM assay In force · From the USPTO record | In force | From the USPTO record | |
| US 9,765,380 | Truncated HER2 SRM/MRM assay In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 27: 3 patents in force now held by others · 14 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 abandoned · 18 no status recorded